will it close out with, page-16

yeh i think it's because we're on the wrong side of the hemisphere. Alnylam are about to close an underwritten public offering of $125M. RNAi is definitely back, just not in the little old sleepy mining town of Oz.

Something we ought to be aware of. The Hausse reckons they might go do some shopping - he suggested Arrowhead. I think one target far more of interest, as has been proven in the past - is Benitec. they took out cross licence options in ddRNAi, and they also bought Nucleonics ddRNAi ip in the fire sale of that flea ridden Co.

For CoH, yes the clinical trials site indicates, as of December, all patients (10) have now been treated. It's not called a phase II due to the cohort being so small i guess, but rather a pilot study. However they are using dosage big enough to test both safety & efficacy, unlike the previous pilot study safety trial. The patients will also go off the HAART medication for this one, so the treatment's effectiveness will really get tested.

I'm not certain how Rossi is. I sure hope he's back on deck - the world needs blokes like him more than ever.